The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Rasagiline Mylan 1 mg tablets

1 milligram(s) Tablet

Mylan S.A.S.EU/1/16/1090/001-012

Main Information

Trade NameRasagiline Mylan 1 mg tablets
Active SubstancesRasagiline
Strength1 milligram(s)
Dosage FormTablet
Licence HolderMylan S.A.S.
Licence NumberEU/1/16/1090/001-012

Group Information

ATC CodeN04BA Dopa and dopa derivatives
N04BA02 levodopa and decarboxylase inhibitor


Licence Issued04/04/2016
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusUnknown


Summary of Product CharacteristicsSearch EMA website
Package LeafletSearch EMA website
Public Assessment ReportSearch EMA website

Generics Information

Interchangeable ListRasagiline 1mg Tablets
Interchangeable List CodeIC0112-039-002
Interchangeable List DocumentPDF of Interchangeable List
« Back